Dr. Apolo on Managing Toxicities With Checkpoint Inhibitors in Bladder Cancer

Andrea B. Apolo, MD
Published: Friday, Dec 01, 2017

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

Apolo says that it is important for urologists to understand proper management of patients with bladder cancer who are undergoing therapy with checkpoint inhibitors.

Investigators are hoping to move checkpoint inhibitors to earlier states of disease, such as muscle-invasive and non-muscle invasive bladder cancer. Urologists will see these patients treated with these agents in their clinic.
 
Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

Apolo says that it is important for urologists to understand proper management of patients with bladder cancer who are undergoing therapy with checkpoint inhibitors.

Investigators are hoping to move checkpoint inhibitors to earlier states of disease, such as muscle-invasive and non-muscle invasive bladder cancer. Urologists will see these patients treated with these agents in their clinic.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x